Search company, investor...


Founded Year



Acquired | Acquired

Total Raised




About Kenet

Kenet is a fabless semiconductor company targeted at portable consumer and communication products. Their intellectual property has foundations in technology developed at the Massachusetts Institute of Technology, Cambridge.

Headquarters Location

300 Unicorn Park

Woburn, Massachusetts, 01801,

United States


Missing: Kenet's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kenet's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Kenet

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Kenet is included in 1 Expert Collection, including Semiconductors, Chips, and Advanced Electronics.


Semiconductors, Chips, and Advanced Electronics

6,250 items

Companies in this collection develop everything from microprocessors to flash memory, integrated circuits specifically for quantum computing and artificial intelligence to OLED for displays, massive production fabs to circuit design firms, and everything in between.

Kenet Patents

Kenet has filed 19 patents.

patents chart

Application Date

Grant Date


Related Topics




Electronic circuits, Electronic amplifiers, Analog circuits, Audio equipment manufacturers, Broadcast engineering


Application Date


Grant Date



Related Topics

Electronic circuits, Electronic amplifiers, Analog circuits, Audio equipment manufacturers, Broadcast engineering



Latest Kenet News

Fitusiran prophylaxis leads to 61% reduction in bleeds among people with hemophilia A or B

Jul 27, 2022

Source: Kenet G, et al. Abstract LB 01.1 Presented at: International Society on Thrombosis and Haemostasis 2022 Congress; July 9-13, 2022; London. Disclosures: Sanofi funded this study. Kenet reports consultant, advisory board or speakers bureau roles with or research funding from Alnylam, Bayer, BioMarin Pharmaceutical, BPL Plasma, CSL Behring, NovoNordisk, Opko Biologics, Pfizer, Takeda, Roche, Sanofi, Shire and uniQure. Please see the abstract for all other researchers’ relevant financial disclosures. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Subscribe ADDED TO EMAIL ALERTS Back to Healio We were unable to process your request. Please try again later. If you continue to have this issue please contact . Back to Healio Almost two-thirds (63.1%) had no treated bleeds while receiving prophylactic fitusiran. Fitusiran demonstrated “statistically significant improvement in health-related quality-of-life measures.” Once-monthly prophylactic fitusiran resulted in significantly fewer bleeding episodes compared with episodic-based on-demand treatment among males with hemophilia A or B with or without inhibitors, according to results of a phase 3 study. Kenet G, et al. Abstract LB 01.1 Presented at: International Society on Thrombosis and Haemostasis 2022 Congress; July 9-13, 2022; London. Use of fitusiran (Sanofi) also led to significantly improved health-related quality-of-life scores, findings presented at International Society on Thrombosis and Haemostasis 2022 Congress showed. Background Prophylaxis is the standard-of-care treatment for patients with hemophilia, according to Gili Kenet, MD, director of Israel National Hemophilia Center at Sheba Medical Center and head of Amalia Biron Thrombosis Research Institute of Tel Aviv University. Historically, the aim of prophylaxis has been to replace the missing clotting factor that corresponded with the type of disease with the intent of preventing bleeding. “Now the bar is rising because the regular administration of hemostatic agents has the goal of preventing bleeding in patients with hemophilia while allowing them to lead active lives and achieve quality of life that is comparable with patients who do not have hemophilia,” Kenet said during a presentation. Fitusiran — a subcutaneous small-interference RNA therapy — has “raised the expectations” of what is possible for the treatment of hemophilia A and B, she said. Prophylactic use of the investigational treatment has shown the ability to significantly reduce annualized bleeding rates compared with on-demand treatment options in previous phase 3 studies , she added. “Fitusiran targets antithrombin to restore specific thrombi generation and rebalance hemostasis without actually replacing the missing population factors,” Kenet said. Methodology The multicenter phase 3 ATLAS-PPX trial enrolled 80 males aged 12 years or older with hemophilia A or B, with (n = 30) or without (n = 50) inhibitors, who had received previous treatment with prophylactic factor or bypassing agents. Kenet and colleagues divided the study into an initial standard-of-care period, when patients continued receiving prophylactic factor or bypassing agents for 6 months, and a treatment period, when patients began taking prophylactic once-monthly subcutaneous fitusiran dosed at 80 mg starting at month 7. Annualized bleeding rate during the standard-of-care and treatment periods served as the study’s primary endpoint. Secondary endpoints included spontaneous annualized bleeding rate, annualized bleeding rate in joints, health-related quality of life and safety. Key findings Sixty-five patients remained eligible for primary endpoint analysis of annualized bleeding rate, including 50 patients with hemophilia A and 15 with hemophilia B. Investigators divided the study into two cohorts — 19 patients with inhibitors (mean age, 27.8 ± 17.1 years) and 46 patients without inhibitors (mean age, 23.5 ± 7.3 years). Researchers reported a median annualized bleeding rate of 0 (95% CI, 0-2.3) among patients who received fitusiran prophylaxis compared with 4.4 (95% CI, 2.2-10.9) for those who received prophylactic factor or bypassing agents. This equaled a statically significant 61.1% reduction in annualized bleeding rate for patients who received fitusiran (P -= .0008). Additionally, 41 patients (63.1%) had no treated bleeds while receiving prophylactic fitusiran during the treatment period. Investigators noted that spontaneous annualized bleeding rate, annualized bleeding rate in joints and health related quality-of-life assessments all showed significant improvement during the treatment period with fitusiran. This included median spontaneous and joint bleeding rates of zero during the treatment period compared with 2.2 for both values during the standard-of-care period. Safety analysis showed 71.6% of patients had a treatment-related adverse event during the fitusiran treatment period, compared with 33.8% in the standard-of-care period. Serious treatment-related adverse events occurred among 13.4% of patients during the fitusiran treatment period, including two patients who discontinued the therapy. No treatment-related deaths occurred during either the standard-of-care or fitusiran treatment periods. Clinical implications Fitusiran prophylaxis resulted in statistically significant reductions in bleeding events vs. standard-of-care treatment among patients with hemophilia A or B, regardless of whether they developed inhibitors, Kenet noted. “[This] resulted in statistically significant improvement in health-related quality-of-life measures,” she said. “Reported adverse events were generally consistent with previously identified risks of fitusiran or what is anticipated in an adult and adolescent population of patients with severe hemophilia A or B, with or without inhibitors.” Read more about

Kenet Frequently Asked Questions (FAQ)

  • When was Kenet founded?

    Kenet was founded in 2002.

  • Where is Kenet's headquarters?

    Kenet's headquarters is located at 300 Unicorn Park, Woburn.

  • What is Kenet's latest funding round?

    Kenet's latest funding round is Acquired.

  • How much did Kenet raise?

    Kenet raised a total of $27M.

  • Who are the investors of Kenet?

    Investors of Kenet include Intersil, Venrock, Charoen Pokphand Group, Kopin and Oak Investment Partners.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.